Protego Biopharma Adds Veteran Biotech Dealmaker John Maraganore to Board as Lead Program Nears Pivotal Trial

New updates have been reported about Protego Biopharma.

Protego Biopharma, a clinical‑stage San Diego biotech focused on small‑molecule drugs that reprogram protein folding, has appointed former Alnylam CEO John M. Maraganore, Ph.D., to its Board of Directors, signaling a strategic strengthening of its leadership as it advances toward late‑stage development. CEO Brent Warner said Maraganore’s track record in navigating complex science and commercialization will be critical as Protego prepares its lead candidate for a pivotal trial in AL amyloidosis, a rare and often fatal systemic amyloid disease.

Maraganore, who built Alnylam from an RNAi research venture into a company with more than $25 billion in market value and five globally approved RNAi medicines, brings extensive experience in scaling platforms, executing partnerships, and driving regulatory approvals that could influence Protego’s partnering and financing strategy. He highlighted protein misfolding as a high‑potential therapeutic frontier and expressed particular interest in Protego’s approach to monogenic protein misfolding disorders, suggesting strategic alignment with the company’s core thesis. His current roles across public and private biotech boards, venture and investment firms, and industry groups also expand Protego’s access to capital, business development channels, and external expertise as it positions its protein‑misfolding pipeline for subsequent clinical and commercial inflection points.